Showing results (71-80 of 162) with videos related to

Sort By:
Pageof 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
Overexpression of HER-2/neu in uterine serous papillary cancerAlessandro D Santin, Stefania Bellone, Murat Gokden, et al.
American Journal of Obstetrics and Gynecology|April 27, 2010
Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitroSarah N Cross, Emiliano Cocco, Stefania Bellone, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 18, 2025
Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical modelsVictoria M Ettorre, Beatrice Conca, Cem Demirkiran, et al.
Gynecologic Oncology|January 12, 2020
Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)Alessandro D Santin, Wei Deng, Michael Frumovitz, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 6, 2011
Trop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: implications for immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibodyEliana Bignotti, Antonella Ravaggi, Chiara Romani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2026
A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine CancerAlessandro D Santin, Dana M Roque, Eric Siegel, et al.
Gynecologic Oncology|June 29, 2025
Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcomaMichelle Greenman, Stefania Bellone, Cem Demirkiran, et al.
Cancer Medicine|September 6, 2024
Preclinical evaluation of avutometinib and defactinib in high-grade endometrioid endometrial cancerTobias Max Philipp Hartwich, Miranda Mansolf, Cem Demirkiran, et al.
Gynecologic Oncology Reports|July 25, 2026
Preclinical in vitro and in vivo activity of trastuzumab deruxtecan against ERBB2-mutated cervical carcinomas with low HER2 expressionNamrata Sethi, Sarah Ottum, Stefania Bellone, et al.
Cancer Research Communications|April 29, 2025
Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous CarcinomaMichelle Greenman, Cem Demirkiran, Stefania Bellone, et al.
Pageof 17